Could Galectin Therapeutics Inc (NASDAQ:GALT) Skyrocket? The Stock Has Too Many Sellers

Galectin Therapeutics, Inc. (NASDAQ:GALT) Logo

Investors sentiment increased to 2.15 in 2019 Q1. Its up 1.09, from 1.06 in 2018Q4. It improved, as 3 investors sold Galectin Therapeutics, Inc. shares while 10 reduced holdings. 17 funds opened positions while 11 raised stakes. 6.26 million shares or 31.05% more from 4.77 million shares in 2018Q4 were reported.
Citadel Limited Liability Company holds 20,411 shares. Stratos Wealth invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Tci Wealth Advsrs holds 300 shares. Cambridge Investment Research Advisors holds 176,222 shares or 0.01% of its portfolio. Alpine Glob Management Ltd accumulated 19,093 shares. Jefferies Group Lc reported 26,800 shares stake. Susquehanna Intl Group Inc Llp reported 444,569 shares stake. D E Shaw And holds 16,350 shares or 0% of its portfolio. California Pub Employees Retirement Sys owns 23,450 shares for 0% of their portfolio. Lpl Fincl Ltd Llc invested in 0% or 31,877 shares. Royal Commercial Bank Of Canada accumulated 1,100 shares. Citigroup holds 0% or 58,373 shares in its portfolio. The Massachusetts-based Geode Mgmt Limited Co has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). 10,000 were reported by Dynamic Advisor Solutions Limited. Blackrock Inc invested in 0% or 595,501 shares.

Since April 5, 2019, it had 10 insider buys, and 0 selling transactions for $20.44 million activity. CALLICUTT JACK W bought $10,075 worth of stock or 2,354 shares. Another trade for 12,849 shares valued at $54,994 was made by LEWIS JOEL on Friday, May 31. Shares for $12,981 were bought by ELDRED KARY on Friday, May 31. OMENN GILBERT S had bought 18,578 shares worth $79,514 on Friday, May 31. Another trade for 4.68M shares valued at $20.03 million was made by Uihlein Richard E on Wednesday, May 29.

The stock of Galectin Therapeutics Inc (NASDAQ:GALT) registered an increase of 2.23% in short interest. GALT’s total short interest was 3.80M shares in August as published by FINRA. Its up 2.23% from 3.71 million shares, reported previously. With 408,100 shares average volume, it will take short sellers 9 days to cover their GALT’s short positions. The short interest to Galectin Therapeutics Inc’s float is 11.04%.

The stock decreased 0.60% or $0.02 during the last trading session, reaching $3.33. About 445,559 shares traded or 28.71% up from the average. Galectin Therapeutics, Inc. (NASDAQ:GALT) has declined 25.70% since August 15, 2018 and is downtrending. It has underperformed by 25.70% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $188.58 million. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 2 analysts covering Galectin Therapeutics (NASDAQ:GALT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Galectin Therapeutics has $11 highest and $11 lowest target. $11’s average target is 230.33% above currents $3.33 stock price. Galectin Therapeutics had 4 analyst reports since February 23, 2019 according to SRatingsIntel. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by FBR Capital on Thursday, March 7. The stock has “Buy” rating by H.C. Wainwright on Thursday, March 7.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: Seekingalpha.com which released: “Gilead’s Mousetrap – Seeking Alpha” on February 15, 2019, also Seekingalpha.com with their article: “Update On Galectin Therapeutics’ Potential Entry Into Cancer Market – Seeking Alpha” published on February 15, 2018, Seekingalpha.com published: “Merck’s Keytruda + Galectin’s Belapectin (GR-MD-02): Thoughts On The Evidence – Seeking Alpha” on April 17, 2019. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: Nasdaq.com and their article: “Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year? – Nasdaq” published on January 30, 2019 as well as Seekingalpha.com‘s news article titled: “Galectin Therapeutics And Belapectin In Phase 3 NASH Cirrhosis: Moving Up – Seeking Alpha” with publication date: April 11, 2019.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.